Ranexa (ranolazine) Extended-release Tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
January 2016
ADVERSE REACTIONS
Post Marketing Experience
Metabolism and Nutrition Disorders
Cases of hypoglycemia have been...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts